Rapid and Efficient Purification of Functional Collectin-12 and Its Opsonic Activity against Fungal Pathogens.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
03
2019
accepted:
21
06
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
25
1
2020
Statut:
epublish
Résumé
Collectin-12 (collectin placenta 1, CL-P1, or CL-12) is a newly identified pattern recognition molecule of the innate immune system. Recent evidences show that CL-12 plays important roles not only in innate immune protection against certain clinically important pathogens but also in scavenging of host molecules, leukocyte recruitment, and cancer metastasis. Furthermore, CL-12 has been shown to be associated with the pathogenesis of human diseases such as Alzheimer's disease and multiple sclerosis lesion development. Therefore, the functional consequence of CL-12 remains intriguing and awaits further elucidation. However, available protocols for the purification of recombinant CL-12 with high purity are laborious and inefficient and hamper further functional studies. Here, we report a simple, rapid, and efficient solution to obtain biologically active CL-12 with high purity. We established stable transfected Flp-In™-CHO cells expressing the recombinant CL-12 extracellular domain in high amounts. Recombinant CL-12 was purified from cell culture supernatants using a 3-step rapid purification procedure utilizing disposable affinity and ion exchange minicolumns. Purified recombinant CL-12 adopted an oligomeric structure with monomers, dimers, and trimers and retained its binding capacity towards the
Identifiants
pubmed: 31482100
doi: 10.1155/2019/9164202
pmc: PMC6701420
doi:
Substances chimiques
COLEC12 protein, human
0
Collectins
0
Opsonin Proteins
0
Receptors, Scavenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9164202Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biochem Biophys Res Commun. 2001 Feb 2;280(4):1028-35
pubmed: 11162630
J Biol Chem. 2001 Nov 23;276(47):44222-8
pubmed: 11564734
J Biochem. 2003 Mar;133(3):271-7
pubmed: 12761161
J Biol Chem. 2005 Jun 17;280(24):22993-9
pubmed: 15845541
Breast Cancer Res Treat. 2007 Jan;101(2):161-74
pubmed: 16850248
J Neurosci Res. 2006 Sep;84(4):874-90
pubmed: 16868960
J Biol Chem. 2007 Jun 8;282(23):17250-8
pubmed: 17420244
Mol Immunol. 2008 Jun;45(11):3278-88
pubmed: 18423602
Mycoses. 2008 Nov;51(6):477-96
pubmed: 18705662
J Biol Chem. 2009 Oct 9;284(41):28263-75
pubmed: 19632990
J Biol Chem. 2011 Feb 4;286(5):3405-17
pubmed: 21106539
J Immunol. 2013 Aug 1;191(3):1324-33
pubmed: 23817411
Biochim Biophys Acta. 2014 Dec;1840(12):3345-56
pubmed: 25199873
J Immunol. 2015 Oct 1;195(7):3365-73
pubmed: 26290605
Scand J Immunol. 2016 Jul;84(1):12-9
pubmed: 27104295
Immunobiology. 2016 Oct;221(10):1058-67
pubmed: 27377710
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):1-14
pubmed: 27864148
Sci Rep. 2017 Mar 20;7:44794
pubmed: 28317919
Sci Rep. 2018 Feb 28;8(1):3821
pubmed: 29491476
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5
pubmed: 9564455